G aucher disease is a recessively inherited lysosomal storage disorder that is caused by a deficiency in glucocerebrosidase activity. The clinical expression is markedly heterogeneous with respect to age of onset, progression, severity, and neurological involvement. The relative incidence of glucocerebrosidase (GC) m utations has been studied extensively for Jewish but not for non-Jewish Caucasian patient populations. T he present survey on mutant GC genotypes prevalent in Gaucher disease in The Nether lands was taken of 72 patients from different genetic backgrounds* This number is more than half the total num ber of affected Gaucher patients to be expected on the basis of the incidence of the disorder in this country. Analysis of nine GC mutations led to the identification of 74% of the mutant GC alleles in patients from 44 unrelated D utch families (i.e., families that have lived in The Netherlands for at least several generations) and of 44% of the mutant GC alleles in patients from nine unrelated families that recently immigrated from both European and non-European countries. The N370S (cDNA 1226G) GC m utation proved to occur most frequently (41%) in the unrelated Dutch patients and less fre quently (6%) in the unrelated immigrant patients and was always associated with the nonneuronopathic (Type 1) form of the disease. Apart from the association of the N370S mutation with Type 1 Gaucher disease, the prognostic value of GC genotyping was limited, since a particular GC genotype did not correlate closely to a specific clinical course, or to a specific relative responsiveness to enzyme-supple m entation therapy. H um M utat 10:348-358, 1997 . © 1997 key w o r d s : glucocerebrosidase; Gaucher disease; glucosylceramide lipidosis; mutation analysis; lysoso mal storage disorder
INTRODUCTION: ANALYSING MUTATIONS IN GAUCHER PATIENTS
Gaucher disease is one of the most frequent lyso somal storage disorders in humans. The disease is due to an autosomal recessively inherited deficiency in lysosomal glucocerebrosidase activity (E.C. 3.2.1.45), resulting in accumulation of its substrate glucocerebroside (also named glucosylceramide) in ma crophages (Beutler and Grabowski, 1995) . Three phenotypes are distinguished on the basis of onset of neurological symptoms: Type 1, the "adult," or nonneuronopathic, form, Type 2, the "infantile," or acute neuronopathic, form, and Type 3, the "juve nile," or subacute neuronopathic, form. Type 1 Gaucher disease is the most prevalent phenotype that varies considerably in age of onset, progression, and severity of clinical manifestation. Common features are hepatosplenomegaly, anemia, thrombocytopenia, and skeletal deterioration (Barranger and Ginns, 1989; Beutler and Grabowski, 1995) .
The defective glucocerebrosidase (GC) gene is located at chromosome lq21 (Barneveld et al, 1983; Ginns et al., 1985) . A 95% homologous pseudogene is located at the same locus on chromosome 1 (Horowitz et al., 1989) . Cloning of the GC gene has allowed the identification of the precise nature of mutations un derlying the enzyme deficiency in patients with Gaucher disease. More than 50 GC mutations have been re ported (for recent reviews on this topic, see Horowitz and Zimran, 1994) . How ever, it should be realised that for some of the abnor malities in the GC gene, it has not been experimentally proven that they are not polymorphisms, but actually lead to a deficiency of glucocerebrosidase.
In some populations a relatively small number of GC mutations accounts for the majority of the de fects in GC alleles of Gaucher patients. In Jewish and non-Jewish Caucasian populations, the N370S (cDNA 1226G) GC mutation is the most prevalent (Amaral et ah, 1993; Horowitz and Zimran, 1994; Lacerda et al., 1994a) , causing synthesis of a catalytically abnormal enzyme (Grace et al, 1990; Ohashi et al., 1991; van Weely et al., 1993) . This mutation has so far not been encountered in the Japanese popu lation (Ida et alM 1995) . The L444P (cDNA 1448C) GC mutation is relatively frequent in the Jewish and non-Jewish Caucasian populations and in Japanese populations Ida et al., 1995) and leads to synthesis of glucocerebrosidase, which is rapidly degraded (Grace et al., 1991; Ohashi et al, 1991; Grace et al., 1994) . Another frequent GC mutation in Ashkenazi Jewish populations is the so-called 84GG insertion (cDNA 84GG), resulting in synthesis of a truncated enzyme due to the gen eration of a frame shift (Beutler et al, 1991) . This mutation has not been found in the non-Jewish Cau casian or Japanese populations Horowitz and Zimran, 1994; Ida et al., 1995) .
Over the last few years much attention has been given to the analysis of GC mutations in Gaucher patients for a variety of reasons. First, accurate iden tification of Gaucher disease carriers is not feasible on the basis of residual enzyme activity in extracts of blood cells or cultured fibroblasts (Daniels and Glew, 1982; Wenger and Roth, 1982) . In principle, genotyping should allow reliable identification of carriers of (known) mutant GC alleles, and knowledge about the relative frequencies of GC mutations in Gaucher patients should facilitate genetic counseling.
Second, it has been attempted to establish a cor relation between GC genotype and severity of Gaucher disease manifestation (see, e.g., Beutler, 1993) . Unfortunately, researchers disagree about the prognostic value of GC genotyping for clinical ex pression of the disorder (see, e.g., Sibille et al, 1993; Sidransky and Ginns, 1994 )-Although the experi ence of most investigators concerning the results of genotyping may not in fact be that different, some prefer to stress the actual clinical variability within each GC genotype, whereas others prefer a statisti cal evaluation of the genotype results. However, con sensus does exist about the important fact that hetero-alfelic or homo-allelic presence of the N370S GC mutation is not associated with a neuronopathic course of the disease (with the exception of one child) (McCabe et ah, 1996) .
Third, it has been suggested that GC genotypes of Gaucher patients could be predictive for their re sponse to enzyme-supplementation therapy and, moreover, would allow recommendations to be made for the type of dosing regimen to be used. However, so far, GC genotyping has not rendered such guide lines .
Some literature data on GC genotypes of Gaucher patients should be carefully interpreted. In general, proportionally more material from severe Gaucher disease cases (neuronopathic phenotypes, or severe nonneuronopathic phenotypes) has been available for mutation analysis. Thus it cannot be excluded that particular mutations have been over-represented. Furthermore, the most impressive data with respect to GC genotypes of Gaucher patients particularly concern Jewish populations, in which Type 1 Gaucher disease occurs relatively frequently Ginns, 1989, Beutler and Grabowski, 1995) .
As in many other countries, Gaucher disease is a rare disorder in The Netherlands. Nevertheless, cli nicians and fundamental researchers have long been interested in it so that a relatively accurate estima tion can be made for the local incidence of the clini cally manifest disorder, being 100-150 patients in the total population of 15,000,000. Both the existence of a national patient society and the collaboration between various clinical genetic centers involved in the bio chemical diagnosis of Gaucher disease allowed us to determine GC genotypes for a high percentage (50-70%) of all Gaucher patients in The Netherlands.
Here, we document the frequency of various GC mutations in families with incidence of Gaucher dis ease that have lived in The Netherlands for several generations and in families that have recently immi grated to The Netherlands. We discuss the prognos tic value of the GC genotypes with respect to the phenotypic manifestation and to the response to en zyme-supplementation therapy.
MATERIALS AND METHODS Gaucher Patients
A diagnosis of Gaucher disease was made in 72 patients from 53 families living in The Netherlands.
The presence of Gaucher disease was either assumed on the basis of characteristic clinical symptoms and/ or the presence of Gaucher cells in bone marrow or liver biopsies, or was investigated because of an affected sibling. The clinical diagnosis was biochemi cally confirmed by the demonstration of a markedly reduced glucocerebrosidase activity in leukocytes and/or urine samples and/or cultured skin fibroblasts (Daniels and Glew, 1982; Aerts et al, 1991) .
Patients were classified as Type 1, 2, or 3 accord ing to the criteria described by Barranger and Ginns (1989) . Two patients showed an unusual manifesta tion of the disease. Patient No. 56 (see Table 2 ) de veloped characteristic clinical signs of Gaucher disease at a very young age. At the juvenile age, he started to suffer from neurological symptoms that were not identified as signs characteristic for Type 3 Gaucher disease. He died at the age of 21 years due to severe pulmonary involvement. Patient No. 57 so far developed no visceral manifestations of Gaucher disease. At the age of 42, neurological abnormalities resembling Parkinsonian disease developed. Although the glucocerebrosidase activities in blood cells and cultured skin fibroblasts of this patient were mark edly reduced, it cannot be excluded that the clinical complications have an unrelated cause.
Only a few of the examined patients were known to have Ashkenazi Jewish ancestry. Such an ethnic background can, however, not be excluded with cer tainty since there have been various episodes of Jew ish immigration in the Low Countries. In our study we distinguish families that have lived in The Neth erlands for several generations (so-called native fami lies) and families that have recently emigrated from European and non-European countries to The Neth erlands (so-called immigrant patients).
We have also analysed the GC genotype in samples from several unrelated Type 1 Gaucher patients that had been sent to us by other laboratories in Europe. These samples came from Czech Republic (n=4), France (n=5), Germany (n=20), Belgium (n=l), and Portugal (n = l).
Analysis of GC Mutations
Genomic DN A was isolated from leukocytes and/ or cultured skin fibroblasts. The analyses of nine GC mutations were performed by restriction-enzyme di gestions upon polymerase chain reaction (PCR) am plification of genomic DNA (for details, see Table  1 ). The primers were manufactured by Pharmacia (Uppsala, Sweden) and chosen in such a way that the pseudogene was not amplified. Restriction-enzymes BsaBI, HphI, Styl, Neil, and BanI were from New England Biolabs (Beverly, MA) and Xhol, MspI, and HincII from Pharmacia. The restriction-enzyme reactions were performed according to the instruc tions of the manufacturers. The resulting fragments were analysed on polyacrylamide gels or agarose gels as described by Sambrook et al. (1989) .
The mutations resulting in the amino acid substi tutions N370S and V394L (cDNA 1297T) were analysed using mismatch PCR, as described by Beutler et al. (1990) for the N370S mutation and by Beutler et al. (1993a) for the V394L mutation, with modifi cations in the primers used. Also, the insertion mu tation 84GG was analysed using mismatch PCR, as described by Beutler et al. (1991) .
The L444R D409H, (cDNA 1342C), and R463C (cDNA 1504T) mutations were analysed using the same upstream and downstream primers (see Table  1 ), The products were digested with different restric tion enzymes.
We did not investigate the presence of the R456G (cDNA 1483C) and V460V (cDNA 1497C) mutations, which are present in the com plex alleles RecNcil and RecTL due to recombi nations with the pseudogene (for a review see Horowitz and Zimran, 1994) . Thus we cannot ex clude that in some cases the L444P mutation was in fact a RecNcil mutation.
Southern Blot Analysis
Genomic DNA was isolated and digested with restriction enzyme SspI (New England Biolabs) ac cording to a previously described procedure (Zimran et al., 1990) . After separation of the fragments on a 0.5% agarose gel and transfer to Hybond (Amersham, Buckinghamshire, UK), hybridisation was performed with radioactively labelled full-length gluco cerebrosidase cDNA.
RESULTS

Incidence of Glucocerebrosidase Genotypes of Gaucher patients
We analysed nine GC mutations, i.e., the N370S, L444F¡ 84GG, IVS24-1 (genomic DNA 1067A), V394L, D409H, R463C, R496H (cDNA 1604A), and a 55-bp deletion at cDNA position 1263-1317, in 72 Gaucher patients who live or have lived in The Neth erlands. An overview of the GC genotypes of the pa tients is presented in Table 2 , including their country of origin. The relative incidence of GC mutations in unrelated Gaucher patients is shown in Figure 1 .
The most common mutation in the so-called na tive Type 1 Gaucher patients, whose families have lived in The Netherlands for several generations, proved to be the N370S GC mutation. In fact, > 90% of these patients carried the N370S GC muta- tion at least in the hetero-allelic form (Table 2A ). The second most common mutation in these patients was the L444P GC mutation, which occurred, how ever, only in the hetero-allelic form, except for one case (Patient No. 56) . All the other mutations tested were not or were rarely detected in these patients. The two unrelated Type 1 patients showing the 84GG insertion (Patients No. 4, No. 32) had Ashkenazi Jewish ancestors, substantiating the claim that this mutation is exclusively found within this ethnic group (Beutler et al, 1991) ,
In the neuronopathic Type 2 as well as Type 3 Gaucher patients, homozygosity for the L444P mu tation is commonly encountered, and this was also the case for the native Types 2 and 3 Gaucher pa tients. None of the investigated neuronopathic pa tients carried the N370S GC mutation.
The analysis of four GC mutations (N370S, The isolation of genomic DNA and analyses of nine muta tions are described in the legend to Table 1. L444R 84GG, and IV S2+1) led to the identifica tion of 79% of the mutant GC alleles of all native Dutch Gaucher patients. The relative incidence of GC mutations in the investigated Gaucher patients who had recently im migrated from both European and non-European countries was different (Table 2B ). Most importantly, the N370S GC mutation occurred less frequently, i.e., in 20% of the immigrant Type 1 Gaucher patients (cf. Fig. ID) . However, the small number of immigrant Gaucher patients, their diverse ethnic background, and the fact that in some cases the par ents were consanguineous do not allow a statement about the statistical significance of the difference in frequency of mutant alleles among native and immi grant Gaucher patients.
In Table 3 , a comparison is made of the inci dence of the GC genotypes of native Type 1 Gaucher patients in The Netherlands with those of patients in other populations. It can be con cluded that the present findings for the Dutch Type 1 Gaucher patients resemble those reported for patients living in other European countries (in cluding Type 1 Gaucher patients in France) (Caillaud et al., 1995) , as well as our own data for 34 patients living in other European countries. Furthermore, Table 3 shows that among Jewish Type 1 Gaucher patients, the N370S GC muta tion is particularly prevalent: > 65% of the GC alleles carried a N370S mutation. It was initially reported that among non-Jewish Gaucher patients, the N370S GC mutation is far less prevalent, con stituting only 23% of the total m utant GC alleles (Horowitz et al., 1993) . However, more recent data indicate that the difference in frequency of this mutation among Jewish and non-Jewish Cauca sian Type 1 Gaucher patients is less spectacular. Among the Type 1 Gaucher patients in the Euro pean countries (summarised in Table 3) , the N370S mutation was present in 47% of the m u tated GC alleles.
Value of GC Genotype With R espect to Manifestation of Gaucher D isease Correlation between GC genotype and severity of Type 1 Gaucher disease
A score taking into account the severity of a variety of clinical symptoms is commonly used to assess the severity of disease m anifestation in Gaucher patients (Zimran et aL, 1992) . The se verity scoring index (SSI) was calculated for 41 Type 1 Gaucher patients. No significant differ ences in disease severity were noted between male and female Gaucher patients with similar geno types. It can be seen in Figure 2 that the SSI did not correlate with specific GC genotypes. M ore over, differences in SSI were observed between siblings carrying the same GC mutations. Patients 5-9 from family 5 (Table 2A ), e.g., had an SSI of 7* 5, 12, 5, and 8, respectively, and patients 24-26 from family 15 showed an SSI of 16, 5, and 3, respectively. W hen GC genotypes of patients were related to individual parameters of disease expres sion, such as splenomegaly, hepatomegaly, hem a tological symptoms, or bone deterioration, a comparable variability was noted (not shown).
In our experience, homozygosity for the L444P GC mutation was not always absolutely linked to a spe cific clinical course. Patient No. 56 (cf . Table 2A) , who developed lethal pulmonary complications due to excessive infiltration of the lungs by storage cells, was found to be homozygous for the L444P GC mu tation. At the age of death (21 years), no neurologi cal abnormalities characteristic for Type 3 Gaucher disease had yet developed. ?/?
FIGURE 2. Correlation between G C genotypes of 41 Type 1
Gaucher patients in The Netherlands and the severity scor ing index. The isolation of genomic D N A and analyses of nine mutations are described in the legend to Table 1 . The severity scoring index (SSI) was determined using the crite ria described by Zimran et al. (1992) .
Asymptomatic individuals
During our studies we noted in at least three un related families the occurrence of individuals with low glucocerebrosidase activities compared with those in control subjects having no clear clinical symptoms related to Gaucher disease, despite the fact that they were older than 65 years. An example is presented in Figure 3 , showing the GC genotypes of members of a family (family 5 in Table 2 ) with Type 1 Gaucher dis ease. In the second generation, five out of nine sib lings were heterogeneously affected patients. AH five patients were compounds for the L444P and N370S GC mutations. Interestingly, the asymptomatic, 80year-old mother proved to be homozygous for the N370S mutation.
Prognostic Value of GC Genotypes of Type 1 Gaucher Patients With Respect to Response to Enzyme-supplementation Therapy
In The Netherlands, 34 Type 1 Gaucher patients are presently treated by enzyme-supplementation therapy, i.e., chronic intravenous supplementation with a modified glucocerebrosidase (alglucerase; marketed by Genzyme, Boston, MA as Ceredase). All patients participate in a co-ordinated study that aims to establish the minimal dose required for a sat isfactory clinical response for each individual (Plollak et al, 1995) , Briefly, patients initially rcceive a low dose of enzyme (1.15 IU/kg body weight) three times a week. On the basis of defined response criteria, the dose is adjusted every half year (doubling, maintenance, or tapering). As previously described (Hollak et ah, 1995) , the response to enzymesupplementation therapy is variable among the patients. No relationship between the various GC genotypes and responsiveness to therapeutic in tervention was noted (data not shown), as also described by Zimran et ah (1994) .
DISCUSSION
The GC genotypes of Gaucher patients in The Netherlands have been analysed in this study. Be cause of the large number of analysed patients (n= 72 from 53 unrelated families), the data are probably representative for this population.
The data obtained in The Netherlands are con sistent with findings (made by several researchers and ourselves) for Gaucher patient populations living in other countries (Table 3) . The most commonly en countered mutation is the N370S GC mutation, which in the homo -and hetero-allelic form is associ ated with a nonneuronopathic clinical course. A n other common defect is the L444P GC mutation. A large proportion of the native Dutch Type 1 Gaucher patients carries both the N370S and the L444P GC mutations. Homozygosity for the L444P GC m u tation was noted for Type 2 as well as for Type 3 Gaucher patients and for one adult patient with an unusual manifestation of Gaucher disease. The observed distribution of homozygotes and heterozygotes for the L444P GC m utation is almost exactly identical to that predicted by the Hardy-Weinberg equilibrium. II 1 2 3 4 5 6 figure 3. G C genotypes in a Dutch family with incidence of Type 1 Gaucher disease. It was noted that the gluco cerebrosidase activity in urine samples and leukocyte extracts from the mother (1.1) was not higher than that in the affected 7 8 9 10 11 12 13 14 15
siblings. The SSI of the symptomatic Gaucher patients was as follows: 7 (II.2), 8 (II.4), 5 (II.6 ) 12 (II.7), and 5 (11.14). A N 3 7 0 S mutated allele is indicated in grey, a L 4 4 4 P mutated allele in black and a wild-type allele in white.
The most important conclusion to he drawn from our investigation is that the (hetero-allelic) pres ence of the N370S GC allele allows prediction of a nonneuronopathic clinical course, as proposed earlier by McCabe et al. (1996) . This conclusion is particularly relevant for those ethnic groups in which the N370S mutation occurs frequently (e.g., the Jewish and non-Jewish Caucasian popula tions). O ur findings for immigrant Gaucher pa tients and those described by Ida et al. (1995) for Japanese patients suggest that the significance of GC genotyping for genetic counseling may be less for other ethnic populations.
Despite the high frequency of the N370S muta tion, relatively few homozygotes for this mutation were identified among the Gaucher patients investi gated by us. The observed distribution of homozy gotes and heterozygotes for the N370S mutation among native Dutch Gaucher patients, 2% and 77%, respectively, differs significantly for that predicted by the Hardy-Weinberg equilibrium, 17% and 48% re spectively. Only the patients in a single Dutch fam ily were found to be homozygous for this mutation. However, in family studies we detected an 80-yearold asymptomatic N370S homozygote. These results suggest that the N370S/N370S GC genotype may usually result in no (or an extremely mild) manifes tation of Gaucher disease. This was also suggested after analysis of the N370S GC gene frequency in the Portuguese population and in the American Ashkenazi Jewish population (Beutler et al., 1993c; Lacerda et aL, 1994b) . Interestingly, a relatively large number of symptomatic, although usually mildly af fected, N370S homozygotes have been noted in Ashkenazi Jewish populations (see Table 3 ) *
The origin of the N370S GC gene mutation in the Dutch population is unclear. As previously noted for Portuguese Gaucher patients (Lacerda et al., 1994a) , the N370S GC mutation in Dutch Gaucher patients is linked to the same P v l.l haplotype as in Ashkenazi Jewish Gaucher patients. This neither proves nor excludes the likely possibility that the N370S mutation was introduced by Ashkenazi Jew ish individuals in The Netherlands.
During our genotype analysis, we observed a pit fall in the assignment of homozygosity for the N370S mutated GC allele. Using a common procedure for the detection of the N370S mutation, we initially assigned the N370S/N370S GC genotype to several Type 1 Gaucher patients from two unrelated families (families 6 and 17 in Table 2 ). However, we observed that one of the parents in each family did not carry a N370S mutated GC allele. In the case of one family, false paternity can be excluded and in the case of the other family, it is extremely unlikely on the basis of the transmission of another inherited abnormality, It was examined by us whether an intragenic dele tion underlay the problems with PCR-based analysis for the N370S mutation. Southern blot analysis of genomic DNA digested with the restriction enzyme Sspl (Zimran et al., 1990) rendered no indications for the presence of a deletion of 100 bp or more. Comparison of the ratios of radioactivity of the bands for the glucocerebrosidase gene and pseudogene did not point to the occurrence of a deletion of the en tire coding region of the glucocerebrosidase gene . We are studying this further. It is evident that special care should be taken to verify apparent homozygosity for a particular mu tation as established with PCR techniques. Ideally, the genotype of patients should be confirmed by those of their parents.
The prognostic value of GC genotypes of Type 1 Gaucher patients with respect to the severity of the manifestation of the disease, or with respect to re sponsiveness to enzyme-supplementation therapy proved to be limited in our experience. Among pa tients with an identical mutant GC genotype, con siderable variability existed with respect to severity of clinical expression and to responses to therapeu tic intervention. This was, in fact, even noted among siblings. We feel that the value ofGC mutation analy sis in countries such as The Netherlands is, there fore, to be found in the exclusion of a neuronopathic course of the disease by identification of the pres ence of the N370S GC allele, as well as accurate iden tification of carriers and presymptomatic patients in families with incidence of Gaucher disease.
It will be of interest to determine the N370S gene frequency in The Netherlands in order to obtain in sight in the incidence of N370S GC homozygosity and its association with actual disease manifestation. At present, random screening for carriers in The Netherlands should not be advocated, since the gen eral outcome of homozygosity for the N370S GC mutation, theoretically the most frequent mutant genotype, is still not known. Consequently, no solid basis is present for adequate genetic counseling that should be associated with carrier testing in the gen eral population.
In conclusion, the results of our investigation in dicate once more that other factors besides the na ture of m utant glucocerebrosidase in Gaucher patients modulate the clinical expression of the dis ease (for a more detailed discussion, see Aerts et al., 1993) . Although GC genotyping of Gaucher patients is re commendable, its prognostic value for disease manifestation is limited.
